Oncology Times Highlights ERX-41
Dallas, Texas. October 10, 2022: etiraRx’s lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled “Molecule Targets Vulnerability in Triple-Negative Breast Cancer,” Dibash Kumar Das, PhD, summarizes the findings published in the recent Nature Cancer article “Targeting LIPA independent of its lipase activity is a […]